Practical DermatologyFDA Approves OTC Switch for Galderma’s Differin Epiduo Acne Gel

📋 Regulatory Action / Label Change

The FDA has switched adapalene/benzoyl peroxide gel from prescription to OTC status for patients 12 and older. Adolescents may now initiate a retinoid-combination regimen independently, shifting the first clinical conversation from prescription request to regimen review.

Professional Impact

• Adolescent patients may present with an established OTC regimen already in use before any clinical encounter, requiring assessment rather than initiation
• OTC availability does not include prescribing guidance; counseling on irritation, sun sensitivity, and correct application remains a clinical responsibility
• The combination targets multiple acne pathways (comedonal, bacterial, inflammatory); differentiate from single-agent OTC options when counseling patients and families
• NPs and PAs in primary care, pediatrics, and urgent care are frequently the clinicians adolescents see for acne concerns; the conversation is shifting from “I need a prescription” to “I’ve already been using this — is it right for me?”
• Retail availability is expected at major chains in summer 2026, driving patient-initiated use ahead of clinical guidance

Action Items

• Update patient and family counseling on OTC availability of this combination option for adolescents 12 and older
• Review for drug interactions or contraindications before endorsing use in patients on concurrent topical or systemic acne therapy
• Clarify application instructions: once daily with sunscreen; retinoid-class irritation is expected early in treatment
• Document OTC use in adolescent patients’ medication histories at well visits
• Recognize that adapalene/benzoyl peroxide is appropriate for mild-to-moderate acne; maintain a clear upgrade pathway to prescription-strength retinoids or oral antibiotics when OTC therapy is insufficient